EUCTR2006-006497-17-IT进行中（未招募）1 期
A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patient with Metabolic Syndrome and Hypercholesterolemia at High Risk for Coronary Heart Disease - ND
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patient has a diagnosis of metabolic syndrome and hypercholesterolemia
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with screening lab values/findings outside required ranges
研究者
相似试验
进行中（未招募）
不适用
A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorderEUCTR2010-019925-33-CZAstraZeneca AB940
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at Moderately High Risk and High Risk for CHDHypercholesterolemiaEUCTR2007-004448-60-LTMerck & Co., Inc.1,293
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Statin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia. - Extended Release Niacin/Laropiprant – LipidsEUCTR2007-002017-39-FRaboratoires Merck Sharp & Dohme - Chibret1,250
已完成
3 期
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)CTRI/2010/091/001491AstraZeneca AB940
进行中（未招募）
1 期
A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorderEUCTR2010-019925-33-LVAstraZeneca AB940